The Amycretin Data Is In: Viking Therapeutics Phase 2 Results Decoded

Viking Therapeutics' VK2735 showed 14.7% weight loss in just 13 weeks — a pace that would project well beyond current GLP-1 medications over a full year. Here's what the Phase 2 data actually means, and what it doesn't.

The next generation of weight loss medications is approaching, and the early data is striking. Viking Therapeutics' VK2735 — a dual GLP-1/amylin receptor agonist — produced 14.7% mean weight loss at the highest dose in a 13-week Phase 2 trial. For context, injectable Wegovy (semaglutide 2.4mg) produced 14.9% weight loss in 68 weeks in the STEP 1 trial. VK2735 achieved comparable percentage weight loss in roughly one-fifth the time.

Before extrapolating too aggressively from that comparison, let's look at what the data actually shows, what questions remain, and what this means for patients considering GLP-1 therapy today.

The Phase 2 Results

Viking's Phase 2 trial enrolled 175 adults with obesity (BMI ≥30) or overweight with comorbidities (BMI ≥27). Participants received subcutaneous VK2735 at escalating doses or placebo for 13 weeks.

The accelerating trajectory is the most significant finding. In most GLP-1 trials, weight loss velocity peaks around weeks 20–30, then decelerates toward a plateau by weeks 52–68. VK2735's weight loss curve was still steepening at week 13, suggesting the 14.7% figure underestimates the medication's full potential over a typical 52-week treatment period.

What Is Amycretin?

VK2735 is a dual agonist — it activates both GLP-1 receptors and amylin receptors. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. It suppresses glucagon secretion, slows gastric emptying, and promotes satiety through different pathways than GLP-1 alone. By targeting both receptor systems simultaneously, VK2735 creates a stronger composite appetite suppression and metabolic effect.

This is the same dual-targeting approach behind Novo Nordisk's CagriSema (semaglutide + cagrilintide), which showed approximately 25% weight loss in Phase 3 trials. VK2735's advantage, if confirmed in larger trials, is that it combines both mechanisms in a single molecule — potentially simplifying dosing and manufacturing compared to CagriSema's two-drug injection.

The Pipeline Landscape: Who's Building What

*VK2735's 13-week result cannot be directly compared to longer trials. Weight loss trajectories decelerate over time; the 13-week number will not extrapolate linearly to 68 weeks.

What This Doesn't Tell Us

Long-term safety is unknown. 13 weeks is not long enough to detect rare adverse events. GLP-1 medications have known class risks (pancreatitis, gallbladder events, thyroid concerns) that may or may not apply to VK2735's dual mechanism. Longer-term data is essential.

Weight loss deceleration is expected. Early-phase weight loss velocity is almost always faster than late-phase velocity. Projecting VK2735's 13-week trajectory to 52 weeks and concluding it will produce 40%+ weight loss is not how pharmacokinetics works. The plateau effect is real.

Availability is years away. Even under optimistic timelines — Phase 3 starts in 2026, results in 2028, FDA review in 2029 — VK2735 is unlikely to be commercially available before 2029 at the earliest. For patients who need treatment now, currently available medications (semaglutide, tirzepatide) remain the evidence-based options.

What This Means for Patients Today

If you're waiting for the "perfect" GLP-1 medication before starting treatment, the pipeline data should not be your reason to delay. Obesity is a progressive disease with compounding health consequences. Every year of untreated excess weight increases cardiovascular risk, insulin resistance, and joint damage. Starting treatment now with an approved medication, then transitioning to a more effective option when it becomes available, is better medicine than waiting.

The pipeline is exciting. But the drugs available today work. Start where you are.

Current Options